US FDA Approval of IND for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with Envafolimab
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") and TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), today jointly announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for the initiation of a Phase 1/2 clinical study of YH001 in combination with envafolimab and doxorubicin for the treatment of sarcoma patients, including patients who have not received prior therapy.
The Phase 1/2 trial will assess the safety and efficacy of YH001 and envafolimab in patients with the rare sarcoma subtypes of alveolar soft part sarcoma and chondrosarcoma and assess the safety and efficacy of the combination of YH001, envafolimab and doxorubicin in the common sarcoma subtypes of leiomyosarcoma and dedifferentiated liposarcoma.
“YH001 was discovered using Biocytogen’s evidence-based in vivo drug efficacy screening platform and has demonstrated a favorable safety profile and promising anti-tumor activity in combination with a PD-1 antibody in an earlier phase 1 clinical study,” said Rong Chen, M.D., Ph.D., VP of Biocytogen, CEO and CMO of Eucure Biopharma. “As an antibody targeting the validated checkpoint CTLA-4, YH001 is expected to play a very important role in immune-oncology therapy. We are glad to learn that the combination therapy of YH001 + envafolimab and doxorubicin received IND approval by the FDA.”
“We are pleased to receive approval from the FDA to initiate our triplet combination therapy study in sarcoma, which includes our potentially best-in-class CTLA-4 antibody YH001 and the only subcutaneous checkpoint inhibitor approved anywhere in the world, envafolimab,” said Charles Theuer, M.D., Ph.D., TRACON’s Chief Executive Officer. “We look forward to enrolling patients in this study and giving patients additional options for their sarcoma treatment.”
YH001 is an IgG1 antibody targeting CTLA-4 that was invented by Biocytogen, the parent company of Eucure Biopharma, and licensed by TRACON. YH001 has shown enhanced antibody dependent cellular cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) in vitro when compared with ipilimumab. In preclinical studies YH001 demonstrated superior T cell activation and superior tumor growth inhibition activity compared to ipilimumab as a single agent and when combined with a PD-(L)1 antibody in human transgenic mouse tumor models. In these models, single agent YH001 depleted regulatory T cells and increased CD8+ T cells in tumor tissue. YH001 has been dosed as a single agent in a Phase 1 trial in China (NCT04699929) and in combination with the PD-1 antibody toripalimab in a Phase 1 trial in Australia (NCT04357756).
About Eucure Biopharma
As a wholly owned subsidiary of Biocytogen, Eucure Biopharma undertakes the mission of clinical development for Biocytogen’s R&D pipelines. Relying on a strong clinical development team and extensive clinical development experience, Eucure Biopharma focuses on antibody drug therapy for oncology and other indications. The company has established a product pipeline for more than 10 targets, with two products in launched phase II multi-regional clinical trials (MRCT) and two in phase I. For details, please visit www.eucure.com.
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM /RenLite® mice platforms for fully human monoclonal and bispecific antibody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop antibody drugs for more than 1000 targets, known as Project Integrum, and has entered ongoing collaborations with dozens of partners worldwide to produce a variety of antibody drugs. The company's pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai and Boston, USA. For more information, please visit www.biocytogen.com.cn.
TRACON is a clinical-stage biopharmaceutical company utilizing a cost-efficient, CRO-independent, product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies. The Company’s clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; YH001, a potential best-in-class CTLA-4 antibody in Phase 1 development; TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships through a profit-share or revenue-share partnership, or through franchising TRACON’s product development platform. TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the United States or who wish to become CRO-independent. To learn more about TRACON and its product pipeline, visit TRACON’s website at www.traconpharma.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
D3 Security’s European Team to Bring Smart SOAR to it-sa Expo&Congress26.9.2023 05:00:00 EEST | Press release
D3 Security, the leader in smart security orchestration, automation, and response (SOAR), today announced it will be demonstrating its Smart SOAR platform at it-sa Expo&Congress, happening 10-12 October, 2023, at the Exhibition Centre in Nuremberg, Germany. The D3 Security team will be at Booth 251 in Hall 7. “D3 is coming to Germany’s leading IT security event because we have the ideal SOAR solution for companies based in Germany, as well as the rest of Europe,” said Amardeep Dhingra, Director of Strategic Alliances at D3 Security. “We already work with world-class automotive, financial services, and managed services clients—all of which are prevalent industries in the German market—so German companies can be confident in our ability to meet their security automation needs.” D3 Security’s growing footprint in Europe includes sales, sales engineering, and system engineering staff, some of whom are based in Germany. D3 Security’s European customers include the Danish managed security se
MOGAS Systems & Consulting Modules Offer Safe and Reliable Solutions for Heavy Oils Refining26.9.2023 04:00:00 EEST | Press release
MOGAS Industries, Inc. (MOGAS) proudly offers the latest feat in engineering for heavy oils refining. MOGAS Systems & Consulting (MS&C) modular units (modules) are fully functional and ready for use in many process plants. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230925096331/en/ MOGAS Systems and Consulting modular unit (Photo: Business Wire) Modules are a favorable choice compared to traditional stick-built (site fabricated) refinery units constructed on-site, which are frequently more expensive and require excessive additional construction costs due to unnecessary pipe, welding, fittings and other components. MS&C modules’ streamlined design provides many benefits to operators, including reduced capital and operations expenditures (CAPEX and OPEX). MOGAS recently produced five high pressure letdown module units for a residue upgrade application, lowering operations risks to personnel and streamlining the unit’s proc
STEMCELL Technologies Partners with Science World to Empower Girls Pursuing Science-related Careers25.9.2023 21:02:00 EEST | Press release
STEMCELL Technologies, Canada’s largest biotechnology company, is pleased to announce it will be the presenting partner of the Girls and STEAM Summit at Science World in Vancouver. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230925955247/en/ STEMCELL Technologies, Canada’s largest biotechnology company, is pleased to announce it will be the presenting partner of the Girls and STEAM Summit at Science World in Vancouver, British Columbia. The Summit, which takes place on November 4, 2023, is a full-day event with workshops, hands-on activities, a keynote presentation, and sessions with experienced mentors who work in STEAM (science, technology, engineering, art and design, and math). “Science is about so much more than what happens in the laboratory. It provides a lens that can instill a deep-seated curiosity in young minds and enrich every aspect of our lives,” said Sharon Louis, Senior Vice President of Research and Devel
AngloGold Ashanti plc Completes the Primary Listing of Its Ordinary Shares on the NYSE and Commences Trading25.9.2023 17:11:00 EEST | Press release
AngloGold Ashanti is pleased to announce that it has today completed its corporate restructuring, with a primary listing of its shares on the New York Stock Exchange (NYSE) and a corporate domicile in the UK. The corporate restructuring was first announced on 12 May of this year and approved by the shareholders of AngloGold Ashanti Limited on 18 August. “The move of our primary listing to the NYSE provides us with improved access to the world’s largest capital market and places us alongside the industry’s highest-valued gold companies,” said AngloGold Ashanti CEO Alberto Calderon. “This signifies an important new era for AngloGold Ashanti strengthening our corporate infrastructure as we continue to focus on taking performance from our world class asset base to the next level.” The ordinary shares of AngloGold Ashanti plc commenced trading on the NYSE today, 25 September 2023, maintaining the ticker symbol AU. Trading in the AngloGold Ashanti Limited American Depositary Shares (ADSs) on
PLIDCO Launches New Line of Hydrogen-Compatible Fittings25.9.2023 17:00:00 EEST | Press release
The Pipe Line Development Company (PLIDCO), the leader in pipeline leak repair and maintenance fittings, announced today a new range of products for use with hydrogen pipelines in response to the emerging transition toward hydrogen and other alternative energy sources. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230925622149/en/ PLIDCO Hydrogen-Compliant Fittings Brochure (Photo: Business Wire) Designed for onshore and subsea high-pressure emergency pipeline repairs and routine pipeline maintenance applications, PLIDCO’s products are ideal for hydrogen, oil, gas, water, chemical, steam, slurry and other piping systems. Its high-pressure fittings are designed and manufactured to meet the highest quality standards, following ASME/ANSI codes and adhering to a strict quality control program. “As the shift toward a hydrogen-based energy system gains traction, we anticipate an emerging need for pipeline maintenance and repair p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom